HomeComparePFE vs HRC

PFE vs HRC: Dividend Comparison 2026

PFE yields 6.20% · HRC yields 11.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HRC wins by $2.21M in total portfolio value
10 years
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →
HRC
HRC
● Live price
11.38%
Share price
$155.96
Annual div
$17.74
5Y div CAGR
40.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.26M
Annual income
$1,423,429.65
Full HRC calculator →

Portfolio growth — PFE vs HRC

📍 HRC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPFEHRC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PFE + HRC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PFE pays
HRC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
HRC
Annual income on $10K today (after 15% tax)
$966.88/yr
After 10yr DRIP, annual income (after tax)
$1,209,915.20/yr
At 15% tax rate, HRC beats the other by $1,186,786.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PFE + HRC for your $10,000?

PFE: 50%HRC: 50%
100% HRC50/50100% PFE
Portfolio after 10yr
$1.15M
Annual income
$725,320.09/yr
Blended yield
62.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
HRC
Analyst Ratings
7
Buy
12
Hold
1
Sell
Consensus: Hold
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PFE buys
0
HRC buys
0
No recent congressional trades found for PFE or HRC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPFEHRC
Forward yield6.20%11.38%
Annual dividend / share$1.72$17.74
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR13.2%40.3%
Portfolio after 10y$51.1K$2.26M
Annual income after 10y$27,210.54$1,423,429.65
Total dividends collected$60.1K$2.14M
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldHold

Year-by-year: PFE vs HRC ($10,000, DRIP)

YearPFE PortfolioPFE Income/yrHRC PortfolioHRC Income/yrGap
1← crossover$9,161$701.38$12,296$1,595.93$3.1KHRC
2$8,610$859.79$15,730$2,573.05$7.1KHRC
3$8,366$1,081.25$21,147$4,316.00$12.8KHRC
4$8,483$1,405.66$30,235$7,608.15$21.8KHRC
5$9,084$1,907.24$46,615$14,263.36$37.5KHRC
6$10,418$2,732.78$78,712$28,834.27$68.3KHRC
7$13,007$4,193.56$148,063$63,841.01$135.1KHRC
8$18,010$7,005.87$315,890$157,462.80$297.9KHRC
9$28,216$12,979.89$778,498$440,495.17$750.3KHRC
10$51,081$27,210.54$2,256,422$1,423,429.65$2.21MHRC

PFE vs HRC: Complete Analysis 2026

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →

HRCStock

Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates in Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as patient exam and diagnostics, patient monitoring, diagnostic cardiology, vision screening, and diagnostics products; and respiratory health products comprising Vest System, VitalCough System, MetaNeb System, Monarch, and Life2000 systems to assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include surgical tables, lights, and pendants; positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables. Further, it is involved in the sales and rental of products to acute and extended care facilities through direct sales force and distributors; sales and rental of products directly to patients in the home; and sales to primary care facilities through distributors. Additionally, the company offers continuum of clinical care, including acute care and primary care, as well as clinical research organizations. Hill-Rom Holdings, Inc. was founded in 1969 and is headquartered in Chicago, Illinois.

Full HRC Calculator →
📬

Get this PFE vs HRC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PFE vs JNJPFE vs MRKPFE vs ABBVPFE vs BMYPFE vs LLYPFE vs SCHDPFE vs JEPIPFE vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.